BiomX, Inc.
(NYSE Amex Equities : PHGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 1.32%697.332.6%$644.85m
MRNAModerna, Inc. -0.55%123.640.0%$634.51m
AMGNAmgen, Inc. -0.34%226.971.4%$624.69m
GILDGilead Sciences, Inc. -1.43%62.861.0%$494.49m
VRTXVertex Pharmaceuticals, Inc. -1.01%283.451.9%$355.83m
ILMNIllumina, Inc. -1.61%190.383.2%$291.37m
SNSSSunesis Pharmaceuticals, Inc. -5.81%4.050.7%$283.11m
BIIBBiogen, Inc. -1.42%197.781.8%$184.42m
SAVACassava Sciences, Inc. -18.00%41.870.0%$173.71m
BNTXBioNTech SE -1.27%128.350.0%$100.39m
NRBONeuroBo Pharmaceuticals, Inc. -6.44%15.540.0%$89.03m
NVAXNovavax, Inc. -6.42%21.0075.6%$85.66m
BMRNBioMarin Pharmaceutical, Inc. -0.09%84.844.2%$76.07m
EXASEXACT Sciences Corp. -2.74%33.4117.6%$71.49m
CRSPCRISPR Therapeutics AG -2.68%63.160.6%$69.53m

Company Profile

BiomX, Inc. operates as a clinical-stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis, and colorectal cancer. The firm discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.